DigiFab® in Patients with Severe Preeclampsia

Status: open

17-019 - [1005180-2] A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects with Severe Preeclampsia

Treatment for Preeclampsia

Contact Us Or call 251-415-1598


This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo. IRB Number 17-019


This trial is sponsored by Velo Bio, LLC.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.